Canada Pharmacy Online Stocks New Blood Thinner Eliquis – An Option In VTE Prevention

Canada (I-Newswire) June 10, 2011 - The recently developed Eliquis (apixaban), a new oral blood thinner, has been highly recommended by Canada Pharmacy Online after the drug’s approval by European regulatory bodies on May 23, 2011 for distribution to 27 countries across Europe. It is proving to be a more effective oral drug for prevention of venous thromboembolic events (VTE) among adults who had undergone elective surgery involving knee or hip replacement.

There is a much higher risk among adults to develop VTE after a major orthopedic surgery including elective total hip or knee replacement which in terms of absolute risk can be between 40 to 60%, if patients have not been given preventive care measures. The new drug is definitely more effective than some of the older drugs available until now. Furthermore, it does not increase the risk of bleeding excessively. Canada Pharmacy Online has been following up on the drug and has decided to make it available worldwide. Apixaban has not yet received a FDA approval for the United States, and it may take some more time to get it.

Successful implementation of the EXPANSE clinical trial program that initiated the ADVANCE-2 and ADVANCE-3 clinical trials has led to the approval of apixaban in Europe. Random trial tests were conducted on over 8,000 patients to test the effectiveness and safety of the drug in comparison to enoxaparin. The drug was administered twice a day in the form of injections, basically to prevent clotting after total hip and knee replacement surgeries.

The drug’s launch in Europe is bound to offer tough competition to warfarin. Pfizer had established that an oral anticoagulant which had a post-surgery 12- to 24- hour window for initiation was being introduced for the first time. The European approval was just the first step towards finding different indications for the drug. Clinical trials would continue over 60,000 patients to find multiple indications that will help prevent strokes and other heart diseases in patients suffering from atrial fibrillation.

Bristol-Myers Squibb had earlier in August 2010 at the European Society of Cardiology meeting at Stockholm presented preliminary data comparing apixaban with aspirin for prevention of stroke, especially in patients who could not take warfarin. The preliminary study was conducted jointly with Pfizer and clearly indicated that apixaban reduced the risk of stroke by 54% compared to aspirin. The results were possible without major increase in bleeding. The drug is likely to compete against Boehringer Ingelheim’s Pradaxa (dagibatran), which has already got approval from CHMP as an effective drug that protects adult patients suffering from nonvalvular atrial fibrillation from getting systemic embolism or strokes.

On the basis of these positive results, Canada Pharmacy Online has decided to dispense the drug through its online pharmacy making sure that the drug reaches patients across the globe at great speed through mail order. The pharmacy has made it possible for patients to buy Eliquis (apixaban) at highly competitive prices with a valid doctor’s prescription. Patients opting for hip replacement surgery are recommended a treatment period of 32 to 38 days while it comes down to 10 to 14 days in the case of knee replacement surgery.

Robert Anderson is specializing in writing articles on how to save on medication by buying from Canadian Pharmacy. For more information about the author and savings on Canadian drugs please visit http://www.canadapharmacyonline.com

About Canada Pharmacy Online:
For more information about Online Pharmacy Reviews visit http://www.pharmacyreviews.net

Company Contact Information
Canada Pharmacy Online
Robert Anderson
202A, 8322-130th Street
V3W 8J9
Phone : 1-604-543-8711